免疫系を活性化する新しい抗がん化学療法(Experimental chemo drug may trick the immune system)

ad

2026-03-17 テキサス大学オースチン校(UT Austin)

テキサス大学の研究チームは、免疫系を活性化させてがんを攻撃させる新しい化学療法薬の可能性を示した。この実験的薬剤は、がん細胞を変化させて免疫系に「異物」として認識させる仕組みを持ち、従来の化学療法とは異なり免疫応答を誘導する点が特徴である。研究では、腫瘍の増殖抑制や免疫細胞の活性化が確認され、より効果的ながん治療法につながる可能性が示唆された。特に免疫療法との併用により治療効果の向上が期待される。本成果は、がん治療戦略の新たな方向性を示す重要な一歩である。

免疫系を活性化する新しい抗がん化学療法(Experimental chemo drug may trick the immune system)
Colon cancer cells under a microscope.

<関連情報>

ウイルスの模倣は免疫原性細胞死を説明するのに役立つ可能性がある Viral mimicry may help explain immunogenic cell death

Matthew S. Levine, Jiexi Li, Lauren I. R. Ehrlich, +2 , and Jonathan L. Sessler
Proceedings of the National Academy of Sciences  Published:March 11, 2026
DOI:https://doi.org/10.1073/pnas.2537547123

Significance

It has long been observed that cancer patients respond differently to the same cytotoxic chemotherapeutic agent. We are proposing here that cytotoxicity-induced viral mimicry contributes to so-called immunogenic cell death and could represent an underappreciated determinant of patient outcome associated with cancer chemotherapy. Viral mimicry as a proposed mechanism of action thus bridges the gap between cytotoxicity and the innate and adaptive immune responses.

Abstract

Viral mimicry may be an underappreciated contributor to chemotherapeutic potency in animal models and patients. This hypothesis is based on studies of a bis-Au(I)-NHC complex that was found to generate a strong anti-tumor immune response in vivo in two different challenge studies using an iKAP colorectal cancer mouse model. RNA profiling of treated cells revealed the stimulation of genes that overlap with those upregulated during a viral infection. The bis-Au(I)-NHC complex generates reactive oxygen species (ROS) through the simultaneous redox cycling of the naphthoquinone moiety and inhibition of thioredoxin reductase with Au(I). This ROS increase causes endoplasmic reticulum stress, activation of the unfolded protein response pathway and upregulation of Ifih1, a gene that encodes for the viral dsRNA sensor MDA5. Activation of MDA5 triggers a strong type I interferon response and expression of chemokine ligand 10 that can recruit immune cells to the treated tumor in a manner analogous to immune responses during viral infection. This proposed mechanism bridges the gap between cytotoxicity and the innate and adaptive immune responses. We suggest viral mimicry may be a key driver of chemotherapy potency in animals and an important determinant of positive outcomes in cancer patients.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました